Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ImmunoProst
- 31 Aug 2018 Biomarkers information updated
- 31 Jul 2018 Status changed from not yet recruiting to recruiting.
- 19 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.